Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers

ABSTRACT: Expression data from patient-derived xenografts of human triple-negative breast cancers

ORGANISM(S): Homo sapiens

PROVIDER: GSE142639 | GEO | 2019/12/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

Project description: Not available

| S-EPMC8662740 | biostudies-literature

BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers

Project description:BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers

| PRJNA597843 | ENA

Role of BET Inhibitors in Triple Negative Breast Cancers.

Project description: Not available

| S-EPMC7226117 | biostudies-literature

Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.

Project description: Not available

| S-EPMC6854488 | biostudies-literature

Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.

Project description: Not available

| S-EPMC7156820 | biostudies-literature

DAPK3 modulates migration and invasion of triple negative breast cancers

Project description:A mass spectrometry (MS)-based kinase inhibitor pulldown assay (KIPA) was applied to analyze 16 patient-derived xenografts (PDXs) leading to the discovery that Death-Associated Protein Kinase 3 (DAPK3) is significantly and specifically overexpressed in triple negative breast cancer (TNBC). Validation studies confirmed the enrichment of DAPK3 at the protein level, independent of RNA expression, in both TNBC cell lines and tumors. Genomic knockout of DAPK3 in TNBC cell lines inhibited in vitro migration and invasion, along with downregulation of an epithelial-mesenchymal transition (EMT) signature. The kinase and leucine-zipper domains within DAPK3 were shown by mutational analysis to be essential for functionality. Notably, DAPK3 was found to inhibit the levels of desmoplakin (DSP), a crucial component of the desmosome complex, thereby explaining TNBC migration and invasion effects. Further exploration with immunoprecipitation-mass spectrometry (IP-MS) identified Leucine-zipper protein 1 (LUZP1) as a strong binding partner of DAPK3, engaging in a leucine-zipper-domain-mediated interaction that protects DAPK3 from degradation. Thus, DAPK3 emerges as a novel regulator of EMT components in TNBC.

2025-05-06 | PXD049187 | Pride

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.

Project description: Not available

| S-EPMC5589983 | biostudies-literature

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.

Project description: Not available

| S-EPMC7934920 | biostudies-literature

Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.

Project description: Not available

| S-EPMC10294332 | biostudies-literature

RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

Project description: Not available